



Golden Jubilee Annual conference of
Mumbai Hematology Group (MHG)

soho  India

Essence of ASH

With international guest faculty

Friday-Sunday

15th to 17th of January 2027

Venue:

Jio World Convention Centre
Bandra Kurla Complex
Bandra (East) Mumbai, India.



Click on the link underneath for registering:
<https://asmh.in/registration/>

The Society of Hematologic Oncology (SOHO)

The Society of Hematologic Oncology (SOHO) is a premier international, non-profit professional organization dedicated exclusively to advancing research, education, prevention, clinical trials, and patient care in the field of hematologic malignancies and related disorders.

Founded in 2012 with its headquarters in Houston, Texas, SOHO was established to address a critical gap in medical societies: while general oncology groups often focus heavily on solid tumors, and standard hematology groups dedicate significant portions to benign blood disorders, SOHO was created to focus exclusively on malignant hematology (such as leukemias, lymphomas, myeloma, and MDS/MPN).

Its global network supports over 12,000 members spanning more than 128 countries, serving a diverse community of clinicians, research scientists, pathologists, nurses, and allied healthcare professionals.





Mumbai Hematology Group

Dear Colleagues & Students,

It is our distinct privilege to invite you to the 50th Golden Jubilee Annual conference of Mumbai Hematology Group (MHG), SOHO India & Essence of ASH.

In an era of digital fatigue, we are proud to announce this as a strictly in-person (physical) summit. This is a deliberate choice to foster the high-level scientific discourse, spontaneous networking, and personal camaraderie that only a face-to-face gathering can provide.

We have curated a faculty of eminent international experts to bridge the gap between global innovations and practical clinical application in both classical and malignant hematology.

Joining them is a "Galaxy" of premier Indian faculty, bringing local context to the latest breakthroughs.

I am delighted to inform you that SOHO (The Society of Hematologic Oncology) India has joined hands with us for this academic event.


We also bring the most critical updates from American Society of Hematology (ASH) directly to you, distilled for maximum impact on your practice.

This is your premier opportunity to reconnect with mentors, engage with peers, and build the professional relationships that define our field.

We anticipate a record turnout this year. We urge you to register early and ensure your place at what promises to be the most vibrant and transformative educational event of 2027.

Let us gather in Mumbai to celebrate science, friendship, and the future of hematology.

Yours sincerely,



Dr. Ruha K. Patil
Secretary, MHG



Dr. M.B. Agarwal
President, MHG



Executive committee

Mumbai Hematology Group

President

Dr. M. B. Agarwal

Vice-President

Dr. S D Banavali

Secretary

Dr. Rucha Patil

Treasurer

Dr. Subhaprakash Sanyal

Members

Dr. VA Arun

Dr. Asha Shah

Dr. Bipin Kulkarni

Dr. Navin Khattry

Dr. Roshan Colah

Dr. Shanaz Khodaiji

Dr. Shrimati Shetty

Dr. Shubhangi Agale

Dr. Vidisha Mahajan

Dr. Vrinda Kulkarni



CO-HOSTS



Singapore Society of Hematology (SSH)
President
Dr. Lee Shir Ying



Hong Kong Society of Haematology (HKSH)
Chairman
Vivien W. M. Mak



Myanmar Society of Haematology (MSH)
President
Prof (Dr). Aye Aye Gyi



Sri Lanka College of Haematologists (SLCH)
President
Dr. Thaneswary Sooriyakumar



Haematology Society of Bangladesh (HSB)
President
Dr Amin Lutful Kabir



Nepalese Society of Medical Oncologists (NESMO)
President
Dr. Sudip Shrestha



Iraqi Society of Hematology (ISOH)
President
Prof (Dr) Alaa Fadhil Alwan



Partnering association

**Malaysian
Society of
Haematology**

President
Dr Haris Abdul Rahman



Golden Jubilee Annual conference of Mumbai Hematology Group (MHG)
SOHO India • Essence of ASH  (With international guest speakers)
Friday-Sunday, 15th to 17th of January 2027



**Messages from the
CO-HOSTS
and Partnering association**



MESSAGE FROM THE PRESIDENT OF



**Malaysian
Society of
Haematology**



Congratulations to the Mumbai Hematology Group on reaching an extraordinary milestone—its 50th Golden Jubilee Annual Conference. Few scientific societies can look back on five decades of sustained excellence, and even fewer continue to evolve with such energy and enthusiasm.

As haematologists, we know that progress rarely happens in isolation. The best ideas are often born over lively discussions after lectures, spirited debates over difficult cases, and friendships forged across borders. Conferences like this provide the perfect setting for all three.

The Malaysian Society of Haematology is honoured to join you as a Partnering Haematology Society. We extend our sincere appreciation to Prof M. B. Agarwal and his team for their warm invitation and vision in bringing together colleagues from across the region. I wish all participants an inspiring meeting, fruitful collaborations, and, of course, the opportunity to enjoy the wonderful hospitality of Mumbai.

I look forward to many more opportunities for our societies to learn from one another and advance haematology together.

Dr Haris Abdul Rahman
President
Malaysian Society of Haematology



Message from the President

Iraqi Society of Haematology (ISOH)



On behalf of the Iraqi Society of Haematology (ISOH), it is our great honor and privilege to join this prestigious meeting as a co-host of SOHO India - Essence of ASH and to celebrate the Golden Jubilee of the Mumbai Hematology Group (MHG).

Reaching fifty years of excellence is an extraordinary milestone, reflecting a remarkable legacy of leadership, innovation, and dedication to advancing hematology and improving patient care. The rapid evolution of hematologic diagnostics and therapeutics makes such meetings indispensable. You create an exceptional opportunity to exchange knowledge, discuss the latest evidence presented at SOHO and ASH, and translate scientific advances into improved patient care. The participation of colleagues from India, Iraq and other different countries demonstrates our shared commitment to strengthening hematology services, fostering research, and improving outcomes for patients throughout these regions. Together, we can bridge knowledge gaps, promote education, and build lasting professional collaborations.

I extend my sincere congratulations to the Mumbai Hematology Group on this historic Golden Jubilee and commend the organizers for bringing together such an exceptional scientific programme. I wish the conference every success and warmly encourage hematologists, oncologists, trainees, and allied healthcare professionals to actively participate in this outstanding educational event.

Prof. (Dr.) Alaa Fadhil Alwan
FRCP (Lond)
Consultant hematologist



Message from the President

Sri Lanka College of Haematologists



On behalf of the Sri Lanka College of Haematologists (SLCH), it is my great pleasure and privilege to extend our warmest congratulations to the Mumbai Hematology Group (MHG) on the remarkable occasion of its 50th Golden Jubilee Annual Conference. Fifty years of sustained commitment to advancing haematology is an extraordinary milestone and a testament to the vision, dedication, and enduring contributions of generations of Haematologists.

The Sri Lanka College of Haematologists is deeply honoured and proud to join this prestigious celebration as a co-host of the Golden Jubilee Annual Conference of MHG, SOHO India & Essence of ASH. This collaboration reflects the strong bonds of friendship and shared commitment that unite our professional societies across borders in our common mission to advance science, strengthen education, foster regional collaboration, and ultimately improve outcomes for patients with haematological disorders.

We sincerely thank Dr. M. B. Agarwal, President of MHG and the entire Organising team for inviting SLCH to be part of this historic occasion. We deeply value this opportunity for collaboration and look forward to strengthening our partnership through future academic, scientific, and professional initiatives.

I extend my warmest congratulations once again to the Mumbai Hematology Group on completing five remarkable decades of excellence and wish the Golden Jubilee Annual Conference every success. May this historic gathering inspire new ideas, foster lasting collaborations, and pave the way for an even brighter future for haematology across our region and beyond.

Dr. Thaneswary Sooriyakumar

President, Sri Lanka College of Haematologists (SLCH)



Message from the President

Haematology Society of Bangladesh (HSB)



Dear Colleagues and Friends,

It is a distinct honour for the Haematology Society of Bangladesh (HSB) to join as a co-host of the 50th Golden Jubilee Annual Conference of the Mumbai Hematology Group (MHG), held in conjunction with SOHO India and Essence of ASH. The attainment of a golden jubilee is a landmark achievement, one that bears testimony to five decades of MHG's steadfast dedication to the advancement of haematology education, research, and clinical excellence.

This conference brings together a distinguished faculty of international and national experts, providing a valuable platform for the exchange of knowledge across both classical and malignant haematology. For colleagues from Bangladesh and across South Asia, such gatherings are instrumental in strengthening regional collaboration and in furthering our shared commitment to improving haematological care.

On behalf of the Haematology Society of Bangladesh (HSB), I extend my heartfelt congratulations to the leadership and organizing committee of the Mumbai Hematology Group on this historic milestone. I take this opportunity to cordially invite colleagues from across the region to join us in Mumbai this January, for what promises to be a truly memorable scientific and professional gathering.

With warm regards and best wishes for the continued success of this esteemed conference.

Prof. Dr. Amin Lutful Kabir, MBBS, M.Phil, FCPS (Haematology)
President, Haematology Society of Bangladesh (HSB)
Professor, Department of Haematology,
Bangladesh Medical University (BMU), Dhaka, Bangladesh



Message from the President

Nepalese Society of Medical Oncologists (NESMO)



On behalf of the Nepalese Society of Medical Oncologists (NESMO), it is a distinct honour to join as co-host of SOHO India & Essence of ASH. Fifty years of successful contribution — the Golden Jubilee of the Mumbai Hematology Group is a proud celebration of a legacy that has shaped hematology in this region.

For resource-limited nations like ours, such gatherings are invaluable. They distil the newest science from ASH and SOHO into practical, affordable care that reaches patients at the bedside. The coming together of Nepal, India, Sri Lanka, Bangladesh, Iraq and Malaysia reflects our shared resolve to strengthen cancer care throughout South Asia.

At NESMO, we believe every patient deserves world-class treatment within their own country. Conferences like this help make that vision real.

I congratulate MHG on this historic achievement, wish the conference resounding success, and warmly encourage every colleague and trainee to participate.

Dr. Sudip Shrestha, MD, FRCP (Edin)
Sr. Consultant Medical Oncologist
President
Nepalese Society of Medical Oncologists (NESMO)



Faculty - National

Dr. Aditya Jandial, Chandigarh	Dr. Nikhil Kumar M, Kochi
Dr. Amit Khurana, Surat	Dr. Nilesh Wasekar, Nashik
Dr. Anil Handoo, Delhi	Dr. Pankaj Malhotra, Chandigarh
Dr. Ankur Ahuja, Pune	Dr. Prantar Chakrabarti, Kolkata
Dr. Arijit Nag, Kolkata	Dr. Priyanka Samal, Bhubaneswar
Dr. Ashish Dixit, Bengaluru	Dr. R. K. Jena, Cuttack
Dr. Avinash Kumar Singh, Patna	Dr. Rajan Kapoor, Leh
Dr. Chandrakala S, Bengaluru	Dr. Rajat Bhattacharyya, Kolkata
Dr. Chirasree Sanyal, Kolkata	Dr. Revathi Raj, Chennai
Dr. Debdatta Basu, Puducherry	Dr. Riya Ballikar, Nagpur
Dr. Dinesh Bhurani, Delhi	Dr. Sachin Jadhav, Bengaluru
Dr. Dinesh Chandra, Lucknow	Dr. Sameer Melinkeri, Pune
Dr. Faheema Hasan, Prayagraj	Dr. Sanjeevan Sharma, Delhi
Dr. Ganesh Jaishetwar, Hyderabad	Dr. Satish Kumar A, Bengaluru
Dr. Hemant Malhotra, Jaipur	Dr. Seema Bhatwadekar, Vadodara
Dr. Jasmina Aluwhalia, Chandigarh	Dr. Sharat Damodar, Bengaluru
Dr. Jasmita Dass, Delhi	Dr. Shilpa Bhartia, Kolkata
Dr. Jina Bhattacharyya, Guwahati	Dr. Siddhesh Kalantri, Nashik
Dr. John Abraham, CMC, Ludhiana	Dr. Sonia Nityanand, Lucknow
Dr. Jyoti Kotwal, Delhi	Dr. Sudha Sinha, Hyderabad
Dr. Kiruthiga K. G., Pune	Dr. Sundar Shewale, Kolkata
Dr. Lalit Kumar, Delhi	Dr. Sunil Bhat, Bengaluru
Dr. M. Joseph John, Ludhiana	Dr. Sunit Lokwani, Indore
Dr. Mahek Trehan, Gurugram	Dr. Sweta Lunkad, Pune
Dr. Maitreyee Bhattacharyya	Dr. Tara Roshni Paul, Hyderabad
Dr. Mallikarjun Kalashetty, Bengaluru	Dr. Tuphan Kanti Dolai
Dr. Manoj Kumar, Ahmedabad	Dr. Vandana Bharadwaj, Bengaluru
Dr. Nataraj K. S., Bengaluru	Dr. Velu Nair, Gandhinagar
Dr. Neeraj Sidharthan, Kochi	Dr. Vikram Mathews, Vellore
Dr. Nidhi Jain, Ahmedabad	Dr. Vinay Bohara, Indore



Faculty - Local

Dr. Aditi Shah Kaskar	Dr. Jyoti Chirmade	Dr. Punit Jain
Dr. Alok Shetty	Dr. Kunal Sehgal	Dr. Purna Kurkure
Dr. Amar Dasgupta	Dr. Lingaraj Nayak	Dr. Purva Kanvinde
Dr. Ambreen Pandrowala	Dr. M. B. Agarwal	Dr. Rajesh Patil
Dr. Anita Nadkarni	Dr. Malay Mukherjee	Dr. Reetu Jain
Dr. Anjana Sainani	Dr. Mamta Manglani	Dr. Ritika Khurana
Dr. Ankita Pandey	Dr. Manisha Madkaikar	Dr. Rucha Patil
Dr. Archana Swami	Dr. Manju Sengar	Dr. Sameer Tulpule
Dr. Arundhati Athalye	Dr. Mukesh Desai	Dr. Sangeeta Mudaliar
Dr. Asha Shah	Dr. Muralidaran C	Dr. Santanu Sen
Dr. Ashish Bakshi	Dr. N. D. Moulick	Dr. Shanaz Khodaiji
Dr. Ayushi Agrawal	Dr. Namita Padwal	Dr. Shilpa Gupta
Dr. Balkrishna Padate	Dr. Naveed Tamboli	Dr. Shrinath Kshirsagar
Dr. Bani B. Ganguly	Dr. Navin Khattri	Dr. Shrutika Java
Dr. Bhavna Parikh	Dr. Nikhil Patkar	Dr. Shweta Bansal
Dr. Bipin Kulkarni	Dr. Nishant Jindal	Dr. Subhaprakash Sanyal
Dr. Darshana Rane	Dr. Omkar Khandkar	Dr. Sujata Sharma
Dr. Dipsha Kriplani	Dr. P. G. Subramanian	Dr. Sumeet Gujral
Dr. Farah Jijina	Dr. Parth Ganatra	Dr. Swati Kanakia
Dr. Gaurav Chatterjee	Dr. Prashant Tembhare	Dr. Tapan Saikia
Dr. Girish Rajadhyaksha	Dr. Prathamesh Kulkarni	Dr. VA Arun
Dr. Hamza Dalal	Dr. Priti Mehta	Dr. Vidhisha Mahajan
Dr. Jai Juvekar	Dr. Prochi Madon	Dr. Vrinda Kulkarni



Faculty - International

Dr. Delphine Rea, France

Dr. Hanny Al-Samkari, USA

Dr. María Victoria Mateos, Spain

Dr. Naval Daver, USA

Dr. Nitin Jain, USA


Dr. Ranjana Advani, USA



Faculty - International



Dr. Delphine Rea, France



Dr. Hanny Al-Samkari, USA




Dr. María Victoria Mateos, Spain



Dr. Naval Daver, USA



Dr. Nitin Jain, USA



Dr. Ranjana Advani, USA



Faculty

from Co-hosts & Partnering associations

Dr. Michelle Poon, Singapore

Dr. Piti Techavichit, Thailand

Dr. Aye Aye Khaing, Myanmar

Dr. Lallindra Gooneratne, Sri Lanka

Dr. Ajay Kumar Jha, Nepal




Faculty - from Co-hosts & Partnering associations



Dr. Michelle Poon, Singapore



Dr. Piti Techavichit, Thailand



Dr. Aye Aye Khaing, Myanmar



Dr. Lallindra Gooneratne, Sri Lanka



Dr. Ajay Kumar Jha, Nepal



Faculty - International




Dr. Delphine Rea, MD, PhD

Professor
President of the French CML Study Group (Fi-LMC)
Hematologist, Attending Physician
Head of the Chronic Myeloid Leukemia Tumor Board
Hematology Department
Saint-Louis Hospital
Paris, France

- Dr. Delphine Rea is appointed at Saint-Louis University Hospital, Paris, France where she works as a physician in the Department of Hematology.
- Her main clinical and research interest focuses on malignant myeloid disorders.
- She is responsible for the Chronic Myeloid Leukemia clinical care and research program.
- She has been the principal investigator or investigator of many academic- or industry-sponsored clinical trials dedicated to CML, including pivotal studies that have led to the approval of tyrosine kinase inhibitors or treatment-free remission studies.
- She belongs to the board of directors of the French cooperative group of CML (Fi-LMC), contributes to the CML project of the European LeukemiaNet, to the organization committee of European School of Haematology (ESH) iCMLf annual conference, to the Society of Hematologic Oncology (SOHO) annual meeting education committee and to the scientific advisory board of iCMLf.



Faculty - International



Dr. Hanny Al-Samkari, MD

Classical Hematologist and Clinical Investigator
The Peggy S. Blitz Endowed Chair in Hematology/Oncology
Co-Director, Hereditary Hemorrhagic Telangiectasia Center
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston
Massachusetts, USA

- Dr. Hanny Al-Samkari is the Peggy S. Blitz Endowed Chair in Hematology/Oncology at the Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School.
- He is a classical hematologist and NIH-funded clinical investigator and clinical trialist.
- He also serves as Co-Director the MGH Hereditary Hemorrhagic Telangiectasia (HHT) Center of Excellence.
- His clinical and research interests are in hemostasis, thrombosis, and hemolysis, with focuses in HHT, immune thrombocytopenia, and hemolytic anemias.
- As a clinical investigator, Dr. Al-Samkari is an internationally recognized expert in the clinical development of novel therapeutics for these disorders and serves as the lead principal investigator for multiple ongoing clinical trials.
- He is the current Executive Editor of Hematology: *The ASH Education Program*, an American Society of Hematology peer-reviewed publication, and has published over 150 peer-reviewed manuscripts.
- His original research has been featured in *The New England Journal of Medicine*, *The Lancet*, *Annals of Internal Medicine*, and *Blood*, among other top peer-reviewed journals in hematology and medicine.



Faculty - International



Dr María-Victoria Mateos, MD, PhD

Consultant Physician
Hematology Department
Associate Professor of Medicine
University of Salamanca
Spain

- Consultant Physician in the Haematology Department.
- Associate Professor of Medicine at the University of Salamanca, Spain
- She is the Director of the Myeloma Program & co-ordinates Clinical Trials Unit in Salamanca's University Hospital Haematology Department.
- She serves as coordinator of GEM (Spanish Myeloma Group), with direct involvement in the design and development of clinical trials.
- She has coordinated many clinical trials in elderly and smoldering MM patients that have profoundly influenced current options for treating these patient populations.
- She is also a member of the IMWG (International MM Working Group), IMS (International MM Society), EHA and ASH.
- She has published over 250 papers in peer-reviewed international journals, some of which have become key references in Myeloma field.
- She is Associate Editor of myeloma in Annals of Haematology since 2011 and has acted as a reviewer for top journals such as NEJM, Lancet and Lancet Oncology.
- Among her invited presentations, she has recently contributed to the educational sessions of EHA from 2012, ASH from 2013 & ASCO 2015 and EHA 2016.
- She has served on the EHA's Scientific Program Committee and Advisory Board since 2013 until 2023, and on the ASH Scientific Committee on plasma cell diseases in 2015-23.
- She is a Councilor on the EHA Board from 2015 for a four-year mandate, member of the Steering Committee for the Society of Hematologic Oncology (SOHO), member of the IMS board and member of the European School of Haematology (ESH) Scientific committee.
- She has published over 200 original papers in international journals. Her areas of interest include multiple myeloma, the biology of plasma cells and the new drugs development.

Faculty - International



Dr. Naval Daver

Co-section, Head AML
Director, Leukemia Research Alliance Program
Professor of Medicine
Department of Leukemia
MD Anderson Cancer Center
Houston, Texas, USA

- Dr. Naval Daver is Co-section, Head AML
- He is Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center (MDACC) in Houston, TX.
- He is a clinical investigator with a focus on molecular and immune therapies in acute myeloid leukemia (AML) and myeloid disease and is principal investigator on more than 25 ongoing clinical trials in these diseases, including multiple potential national and international registration studies and label enabling trials.
- These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel and rational combinations of targeted, immune, and cytotoxic agents, and identifying and overcoming mechanisms of resistance.
- He is especially interested in developing FLT3 inhibitor based combinations, monoclonal antibodies, immune checkpoints, CD47, NK and T-cellular therapy approaches, as well as combinations of targeted and apoptotic therapies in AML, and he is leading a number of these trials.
- He has published over 450 peer-reviewed PubMed indexed manuscripts and is on the editorial board of hematology journals.
- He also serves as Chair on numerous international leukemia meetings and educational platforms.

Faculty - International




Dr. Nitin Jain

Professor
 Department of Leukaemia
 MD Anderson Cancer Center
 Houston, Texas, USA

- Dr. Nitin Jain, M.D., is a Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA.
- He earned his medical degree from the All India Institute of Medical Sciences (AIIMS), New Delhi, India in 2002.
- He completed Internal Medicine residency at the Medical College of Wisconsin, Milwaukee, Wisconsin.
- He then completed a year of clinical fellowship in Leukemia at MD Anderson Cancer Center followed by another year of Leukemia research fellowship at Memorial Sloan-Kettering Cancer Center in New York.
- He then pursued fellowship in Hematology/Oncology at the University of Chicago. He joined as a faculty member in the Department of Leukemia at MD Anderson Cancer Center in 2012.
- He treats patients with acute and chronic leukemia with focus of patients with chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL).
- His research interests focus on new drug development for patients with leukemia, especially CLL and ALL.
- He is Principal Investigator of several investigator-initiated phase I-II clinical trials, including combination targeted therapies (ibrutinib and venetoclax) in CLL, combination of ibrutinib and chemotherapy (iFCG regimen) in CLL, checkpoint inhibitors in Richter transformation, trial with JAK2 inhibitor ruxolitinib in Ph-like ALL, novel CD22 antibody drug conjugate in B-ALL, venetoclax + chemotherapy in B- and T-ALL, and off-the-self allogeneic CART in B-ALL.
- The trial combining ibrutinib and venetoclax was published in New England Journal of Medicine in 2019.
- He has published papers in prominent journals including NEJM, Journal of Clinical Oncology, Blood, Clinical Cancer Research, Cancer, Leukemia & Lymphoma, Leukemia Research and others.
- He has won many awards during his career including Sardari Lal Kalra Gold Medal in Microbiology from AIIMS and Merit Award from the American Society of Clinical Oncology (ASCO).
- He secured first rank at the national level in India in the medical school (AIIMS) entrance examination.
- He received High-Impact Clinical Research Support Award from MD Anderson Cancer Center in the year 2014 and 2016.
- He has served as a faculty on American Society of Hematology CRTI workshop for year 2017 and 2018.
- He served as a speaker at the education session on CLL at ASH 2018 and at ASH Highlights of North America, Mediterranean, and Latin America.
- He is recipient of Sabin Family Foundation Award in 2018. In 2020, he received MD Anderson Faculty Scholar award.



Faculty - International



Dr. Ranjana Advani, M.D.
Saul A Rosenberg Professor of Lymphoma
Stanford Cancer Institute
Stanford, California, USA

- Ranjana H. Advani, MD is the Saul Rosenberg Professor of Lymphoma and serves as the Physician Leader of the Lymphoma Clinical Care Program at Stanford Cancer Institute, Stanford, California, USA
- She specializes in research and treatment of Hodgkin and non-Hodgkin lymphomas and has developed a broad collaborative investigative program, encompassing clinical trials and translational correlates.
- She is the Principal Investigator on numerous clinical trials.
- She currently serves on the National Comprehensive Cancer Network (NCCN) non-Hodgkin and Hodgkin Lymphoma (chair) guidelines panel, Lymphoma Core Committee of the Eastern Cooperative Oncology Group (ECOG) and the National Cancer Institute Lymphoma Steering Committee.
- Board Certification: American Board of Internal Medicine, Medical Oncology (2009)
- Fellowship: Stanford University Hematology and Oncology Fellowship (1996).
- Residency: Stanford University Internal Medicine Residency (1990).
- Internship: Santa Clara Valley Medical Center Internal Medicine Residency (1987)
- Medical Education: Bombay University (1982)

Faculty - from Co-hosts & Partnering associations



Dr. Michelle Poon

Adjunct Associate Professor
Sr. Consultant, Division of Haematology
Dept of Haematology-Oncology
National University Cancer Institute
Singapore

- Dr. Michelle Poon is a Senior Consultant at the Dept. of Haematology-Oncology at National University Cancer Institute (NCIS), Singapore.
- After receiving her undergraduate medical degree from the National University of Singapore in 2001, she continued her internal medicine training before obtaining her membership from the Royal College of Physicians of the United Kingdom in 2004.
- She then undertook her advanced specialist training in haematology and obtaining her membership from the Royal College of Pathologists of the United Kingdom for haematology in 2009.
- She continues to be active in both UG and PG training for haematology and is currently an assistant professor with the Department of Medicine, Yong Loo Lin School of Medicine, Singapore.
- She has a special interest in lymphoproliferative disorders and hematopoietic stem cell transplantation.
- She underwent a one-year postdoctoral fellowship programme at the MD Anderson Cancer Center in the USA in 2012 to pursue this interest, especially in the use of hematopoietic transplantation and immunotherapy to treat lymphomas.
- Since her return, she has been actively involved in investigator initiated and pharmaceutical sponsored trials for lymphoproliferative disorders and hematopoietic transplantation.
- Her present research interests are in using novel clinical therapies for the management of patients with lymphoid malignancies (especially ALL and lymphoma) as well as clinical haematopoietic stem cell transplantation for adults with haematological diseases.
- She has also published in several peer-reviewed journals and presented at regional and international meetings.



Faculty - from Co-hosts & Partnering associations



Dr. Piti Techavichit, M.D.

Hematologist and oncologist

Division of Hematology


Department of Pediatrics

The Faculty of Medicine

Chulalongkorn University & King Chulalongkorn Memorial Hospital.
Thailand



Faculty - from Co-hosts & Partnering associations



Dr. Aye Aye Khaing
Myanmar



Faculty - from Co-hosts & Partnering associations



Dr. Lallindra Gooneratne, MBBS, MD (Haematology)

FRCPath (UK), FCCP

Chair, Professor of Pathology

The University of Colombo &

Honorary Consultant Haematologist to the medical professorial unit

National Hospital of Sri Lanka, Colombo, Sri Lanka

- He is Director of clinical haematology and bone marrow transplantation at Asiri Central hospital, Colombo, Sri Lanka.
- In addition to his interest in haemato-oncology and pioneering work in bone marrow transplantation in Sri Lanka, one of his main research interests is in acquired coagulopathies.

Faculty - from Co-hosts & Partnering associations



Dr Ajay Kumar Jha, MBBS, MD (Pediatrics)
DM (Hematology & Oncology)
Sr. Consultant Hematologist
Vayodha Hospital
Kathmandu
Nepal

- He did DM in Hematology & Oncology from PGIMER, Chandigarh, India (2012)
- He did MD Pediatrics from Kasturba Medical College, Manipal, Bengaluru, India (2006) & MBBS from B.P. Koirala Institute of Health Sciences, Nepal (2000).
- He is senior academic clinician and health science leader with over 25 years of experience in medical education, tertiary care, pediatric and adult hematology-oncology, and institutional development.
- Currently, serving as Chair of Hemato-Oncology at Kathmandu University, with extensive experience in academic leadership, faculty development, curriculum oversight, research supervision, and national-level health planning.
- He has proven track record in establishing new departments, mentoring postgraduate programs, and representing Nepal in international academic and clinical forums.

His areas of interest

- Academic leadership & health science governance
- Pediatric & adult hematology-oncology
- Bone marrow transplantation (autologous & allogeneic)
- Curriculum development & postgraduate training
- Clinical research & translational medicine
- Oncology service development in low-resource settings
- Quality assurance, ethics & patient safety




Lectures by international faculty




Dr. Delphine Rea, France

- a. New drugs to in CML
- b. Genomic abnormalities in CML: Should AGA drive 1st line treatment choices?
- c. Combination therapies in CML
- d. TFR: next steps
- e. Case discussion session



Dr. Hanny Al-Samkari, USA

- a. Emerging Novel Therapies in Immune Thrombocytopenia
- b. Modern Optimized Treatment of Chemotherapy-induced Thrombocytopenia
- c. Emerging Novel Therapies in Hereditary Hemorrhagic Telangiectasia
- d. Pyruvate Kinase Activation in Thalassemia and Rare Red Cell Disorders
- e. Thromboembolism in ITP
- f. Optimized Use of TPO-RAs
- g. Case discussion session



Dr. María Victoria Mateos, Spain

- a. Smoldering Myeloma: What is the appropriate management in 2027?
- b. Management of Newly Diagnosed Myeloma patients in 2027
- c. Management of MM patients in early relapses
- d. How to manage today patients in late advanced stages of the disease
- e. Case discussion session




Dr. Naval Daver, USA

- a. Optimizing frontline Intensive chemotherapy approaches in 2027
- b. Targeted therapies in AML: optimal timing, use and response monitoring
- c. Management of frontline MDS: Key updates for 2027
- d. Case discussion session



Dr. Nitin Jain, USA

- a. How do I treat Firstline CLL in 2027 ?
- b. New emerging drugs in CLL: role of BTK degraders and CAR-T
- c. CD19 CAR-T as consolidation treatment in adult B-ALL: an emerging paradigm
- d. CAR-T in T-ALL: an unmet medical need.
- e. Case discussion session



Dr. Ranjana Advani, USA

- a. Non-Hodgkin Lymphoma: highlights from ASH 2026
- b. Hodgkin Lymphoma: highlights from ASH 2026
- c. Controversies in management of Early Stage Hodgkin Lymphoma
- d. How do I treat newly diagnosed DLBCL ?
- e. Case discussion session



Lectures by guests from co-hosts and partnering associations




A/Prof Michelle Poon, Singapore

Lecture title:



Dr. Piti Techavichit, Thailand

Lecture title:



Prof Aye Aye Khaing, Myanmar

Lecture title:



Prof. Lallindra Gooneratne

Lecture title:
Cancer-associated thrombosis: Risk assessment and treatment



Dr Ajay Kumar Jha, Nepal

Lecture title:



Paper presentation (oral or poster best paper award)

Deadline for submitting the detailed abstract of the paper: 1st December 2026 (5 pm).
(to send the email to mbagarwal1@gmail.com)

- Following details are required before **1st November 2026 (5 pm)**.

This information has to be final and cannot be modified later.

In general, case reports will not be accepted unless they have extraordinary work-up and an impact factor.

Please indicate whether paper is for oral or poster best paper award presentation

(please tick one):

1. ☐ Oral presentation 2. ☐ Poster presentation

- Title of the paper:

- Name of first author:

Dr / Mr / Ms _____
(surname) (first name) (middle name)

(Presenting author must be the first author. Paper can be from Mumbai or any other part of India)

- Names of other authors in order:

- Designation of the first author:

- Affiliations of the first author:

- Details of the department and institutions of the co-authors:

- Email ID of the presenting author: _____

- Mobile number of the presenting author: _____

- Deadline for submitting the detailed abstract of the paper: 1st December 2026 (5 pm).

- A sample copy of the abstract is attached.

Sample abstract

Please select one : This paper is for Oral / Poster best paper award session

First Report of Molecular Characterization of Congenital Dyserythropoietic Anaemia Type I with a CDAN1 gene mutation diagnosed by Next Generation Sequencing panel

Presenting author: Arati Nandan Saptarshi

Co-authors: Rashmi Dongerdiye, Tejashree Anil More, Dr. Prabhakar S. Kedar

ICMR-National Institute of Immunohaematology, 13th floor, New Multistoried Building, KEM Hospital, Parel, Mumbai 400012

Abstract:

Background: Congenital dyserythropoietic anaemias (CDAs) are a rare, heterogeneous group of disorders characterized by ineffective erythropoiesis. CDA I is very rare and caused due to mutations in the CDAN1 or c15orf41 gene. There is no report on the molecular characterization of CDA I in the Indian population. An 8-year-old transfusion-dependent patient was referred for haemolytic anaemia workup. Common causes of congenital haemolytic anaemia were ruled out. A bone marrow aspiration study showed erythroid hyperplasia with mild dyserythropoiesis. Thus, the patient was considered for molecular characterization using next-generation sequencing.

Objective:

Diagnosis of unexplained congenital anaemia using next-generation sequencing.

Method:

Next-generation sequencing panel was used for identification of the disease-causing variant; bioinformatics tools were used to predict pathogenicity of the variant and functional validation was performed by gene expression studies using quantitative real-time PCR.

Results:

Red cell membrane, enzyme, hemoglobinopathy, and autoimmune hemolytic anaemia studies were normal. Bone marrow aspiration study showed erythroid hyperplasia with mild dyserythropoiesis. The patient showed c. 2671C>T, p. Arg891Cys variant in the CDAN1 gene using next-generation sequencing. Bioinformatics tools like SIFT, PolyPhen 2.0 predicted the variant to be damaging and deleterious. The expressions of CDAN1 and c15orf41 genes studied using quantitative real-time PCR were significantly reduced as compared to healthy controls.

Conclusion:

Next-generation sequencing confirmed the diagnosis of CDA I in a patient who underwent excessive investigation earlier. CDA, being clinically similar to other prevalent causes of anaemia, should be kept in mind especially when the common causes have already been ruled out. Further, the use of in-silico tools and gene expression analysis validated the functional impact of this variant.

Correspondence:

Arati Nandan Saptarshi, PhD Student, ICMR - National Institute of Immunohaematology, 13th floor, NMS Building, KEM Hospital Campus, Parel, Mumbai - 400012

Email ID: arati611@gmail.com

Cell: 8550903330



Golden Jubilee Annual conference of Mumbai Hematology Group (MHG)
SOHO India • Essence of ASH (With international guest speakers)
Friday-Sunday, 15th to 17th of January 2027



Registration details

Category	Up to 30th September 2026	Up to 31st October 2026	Up to 30th November 2026	From 1st December 2026 onwards including Spot Registration
MHG members *	₹ 2000	₹ 4000	₹ 6000	₹ 8000
Students **	₹ 1000	₹ 2000	₹ 3000	₹ 4000
Delegates	₹ 3000	₹ 6000	₹ 9000	₹ 12000
Trade Registration	₹ 5000	₹ 10000	₹ 15000	₹ 20000
International Delegate	\$ 200	\$ 300	\$ 400	\$ 500

Note: * Membership number must be forwarded.

** Proof to be submitted

Registration fee is non-refundable

Click on the link underneath for registering:

<https://asmh.in/registration/>



Under the aegis of

Mumbai Hematology Group

Hematology Centre, Ghamat Lodge,
804-A, Dr. B. Ambedkar Road, Dadar TT, Mumbai 400014.

Email ID: mbagarwal1@gmail.com Website: www.mhgindia.com